» Articles » PMID: 10971600

Glyceryl Trinitrate Induced Headache in Migraineurs - Relation to Attack Frequency

Overview
Journal Eur J Neurol
Publisher Wiley
Specialty Neurology
Date 2000 Sep 6
PMID 10971600
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Glyceryl trinitrate, a prodrug of nitric oxide, induces a mild to moderate headache in healthy subjects, whilst migraineurs develop a more severe headache, resembling spontaneous migraine attacks. In order to investigate whether this increased nitric oxide sensitivity depends upon the frequency of spontaneously occurring migraine attacks, intravenous infusion of glyceryl trinitrate (0.5 microg/kg/min) was given to 15 migraine patients with rare attacks (</=4 attacks/year) of migraine without aura. Fourteen age-matched migraine patients with frequent attacks of migraine without aura (>/=12 attacks/year) and 14 healthy subjects served as controls. No significant difference between the migraine groups for any of several parameters was detected, although the trend was always towards more headaches in frequent migraineurs. Both migraineurs with frequent and rare attacks experienced a headache that was significantly more severe, longer lasting, and fulfilled the diagnostic criteria for migraine without aura more often, compared to the healthy subjects (P = 0.0001). Conclusively, supersensitivity to glyceryl trinitrate in migraineurs seems to be related to a basic - probably genetically determined - pathophysiological mechanism involving nitric oxide, and not to the environmental influences, which to a large extent determine the expression of migraine.

Citing Articles

Provocation of attacks to discover migraine signaling mechanisms and new drug targets: early history and future perspectives - a narrative review.

Olesen J J Headache Pain. 2024; 25(1):105.

PMID: 38902612 PMC: 11188241. DOI: 10.1186/s10194-024-01796-1.


Genistein mitigates nitroglycerine-induced migraine: modulation of nitric oxide-mediated vasodilation and oxidative stress.

Chaudhary S, Singh L, Kaur M, Kadyan P Metab Brain Dis. 2024; 39(5):821-831.

PMID: 38795260 DOI: 10.1007/s11011-024-01360-5.


Future targets for migraine treatment beyond CGRP.

Al-Hassany L, Boucherie D, Creeney H, van Drie R, Farham F, Favaretto S J Headache Pain. 2023; 24(1):76.

PMID: 37370051 PMC: 10304392. DOI: 10.1186/s10194-023-01567-4.


Nitroglycerin as a model of migraine: Clinical and preclinical review.

Sureda-Gibert P, Romero-Reyes M, Akerman S Neurobiol Pain. 2023; 12:100105.

PMID: 36974065 PMC: 10039393. DOI: 10.1016/j.ynpai.2022.100105.


Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences.

Ashina H, Christensen R, Ashina M J Headache Pain. 2022; 23(1):87.

PMID: 35870898 PMC: 9308906. DOI: 10.1186/s10194-022-01464-2.